ZA969722B - Pharmaceutical formulations. - Google Patents

Pharmaceutical formulations.

Info

Publication number: ZA969722B
Authority: ZA; South Africa
Prior art keywords: pharmaceutical formulations; formulations; pharmaceutical
Prior art date: 1995-11-21

Application number

ZA9609722A

Other languages

English (en)

Inventor

Ross James Macrae

Janet Sarah Smith

Original Assignee

Pfizer Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-21

Filing date

1996-11-20

Publication date

1998-05-20

1996-11-20 Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev

1998-05-20 Publication of ZA969722B publication Critical patent/ZA969722B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA9609722A 1995-11-21 1996-11-20 Pharmaceutical formulations. ZA969722B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
ZA969722B true ZA969722B (en)	1998-05-20

Family

ID=10784188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9609722A ZA969722B (en)	1995-11-21	1996-11-20	Pharmaceutical formulations.

Country Status (29)

Country	Link
EP (1)	EP0862437A1 (fr)
JP (1)	JPH10513481A (fr)
KR (1)	KR19990071505A (fr)
CN (1)	CN1215993A (fr)
AP (1)	AP718A (fr)
AR (1)	AR004335A1 (fr)
AU (1)	AU709560B2 (fr)
BG (1)	BG102438A (fr)
BR (1)	BR9611626A (fr)
CA (1)	CA2232715A1 (fr)
CO (1)	CO4480020A1 (fr)
CZ (1)	CZ155498A3 (fr)
GB (1)	GB9523752D0 (fr)
HR (1)	HRP960554A2 (fr)
HU (1)	HUP9903734A3 (fr)
IS (1)	IS4706A (fr)
MA (1)	MA26410A1 (fr)
MX (1)	MX9804008A (fr)
NO (1)	NO982302L (fr)
NZ (1)	NZ322053A (fr)
OA (1)	OA10687A (fr)
PE (1)	PE22898A1 (fr)
PL (1)	PL326981A1 (fr)
SK (1)	SK63098A3 (fr)
TN (1)	TNSN96141A1 (fr)
TR (1)	TR199800902T2 (fr)
WO (1)	WO1997018814A1 (fr)
YU (1)	YU62096A (fr)
ZA (1)	ZA969722B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945125A (en) *	1995-02-28	1999-08-31	Temple University	Controlled release tablet
JP2002508315A (ja) *	1997-12-16	2002-03-19	ファイザー・プロダクツ・インク	性的不能の治療に有効な組合せ
EA003101B1 (ru)	1998-03-19	2002-12-26	Бристол-Майерз Сквибб Компани	Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
GT199900061A (es) *	1998-05-15	2000-10-14	Pfizer	Formulaciones farmaceuticas.
EP0974343B1 (fr) *	1998-07-22	2004-09-29	Pharma Pass II LLC	Procédé de préparation d'une composition solide contentant du metoprolol
EP0987020A1 (fr) *	1998-09-04	2000-03-22	Pharma Pass LLC	Composition contenant du metoprolol et procédé de préparation
CO5140079A1 (es) *	1998-10-14	2002-03-22	Novartis Ag	Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) *	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) *	2001-09-14	2003-03-27	Pawan Seth	Pharmaceutical composition comprising doxasozin
US6723340B2 (en) *	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1680078A2 (fr) *	2003-10-17	2006-07-19	Ranbaxy Laboratories, Ltd.	Formulations matricielles de doxazosine a administration orale
WO2005107702A2 (fr) *	2004-05-11	2005-11-17	Glenmark Pharmaceuticals Limited	Compositions pharmaceutiques vaginales mucoadhesives a liberation prolongee
KR100574554B1 (ko) *	2004-05-28	2006-04-27	한미약품 주식회사	니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) *	2004-11-20	2007-02-07	대우약품공업주식회사	독사조신을 포함하는 서방성 정제
CA2619035A1 (fr) *	2005-08-22	2007-03-01	Novartis Ag	Compositions pharmaceutiques
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
MX2008013675A (es)	2006-04-26	2009-03-06	Supernus Pharmaceuticals Inc	Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal.
CN101437823B (zh)	2006-05-04	2014-12-10	勃林格殷格翰国际有限公司	多晶型
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
CN100396282C (zh) *	2006-07-25	2008-06-25	山东省医药工业研究所	甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar) *	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2262484B1 (fr)	2008-03-11	2013-01-23	Depomed, Inc.	Formes médicamenteuses à libération étendue de rétention gastrique comprenant des combinaisons d'un analgésique non opioïde et d'un analgésique opioïde
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI478712B (zh)	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) *	2008-12-17	2010-12-24	동아제약주식회사	유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
CN102307577A (zh)	2009-02-13	2012-01-04	贝林格尔.英格海姆国际有限公司	包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
CA2758976C (fr)	2009-04-20	2015-02-03	Alain Baron	Therapies a base de ligand de recepteur chimiosensible
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
CA2782179C (fr)	2009-11-27	2020-06-23	Boehringer Ingelheim International Gmbh	Traitement de patients diabetiques genotypes par des inhibiteurs de dpp-iv tels que la linagliptine
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
EP2590634B1 (fr)	2010-07-09	2016-03-09	BHV Pharma, Inc.	Système d'administration à libération immédiate/retardée en combinaison pour des médicaments à courte demi-vie comprenant de la rémogliflozine
SG189444A1 (en)	2010-10-19	2013-05-31	Elcelyx Therapeutics Inc	Chemosensory receptor ligand-based therapies
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
SG191855A1 (en)	2011-01-07	2013-08-30	Elcelyx Therapeutics Inc	Chemosensory receptor ligand-based therapies
CN102058555A (zh) *	2011-01-13	2011-05-18	北京汇诚瑞祥医药技术有限公司	一种多沙唑嗪控释片
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102188431A (zh) *	2011-05-09	2011-09-21	浙江九旭药业有限公司	甲磺酸多沙唑嗪缓释片及其制备方法
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en)	2011-05-17	2014-02-25	Mallinckrodt Llc	Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en)	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013158928A2 (fr)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Thérapies à base de ligand de récepteur chimiosensoriels
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
EP3003297A4 (fr)	2013-06-05	2017-04-19	Synchroneuron Inc.	Formulations d'acamprosate, procédés d'utilisation de celles-ci, et combinaisons comprenant celles-ci
WO2015128453A1 (fr)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Utilisation médicale d'un inhibiteur de dpp-4
CN105616378A (zh) *	2014-10-31	2016-06-01	康普药业股份有限公司	一种氟康唑胶囊及其制备方法
NZ747331A (en)	2016-06-10	2025-06-27	Boehringer Ingelheim Int	Combinations of linagliptin and metformin
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198386B (it) *	1982-07-06	1988-12-21	Lepetit Spa	Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
PT98374A (pt) *	1990-07-23	1994-01-31	Alza Corp	Dispositivo osmotico para administracao sistemica de nicotina e processo nele baseado

1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
1996
- 1996-11-11 CA CA002232715A patent/CA2232715A1/fr not_active Abandoned
- 1996-11-11 EP EP96938215A patent/EP0862437A1/fr not_active Withdrawn
- 1996-11-11 PL PL96326981A patent/PL326981A1/xx unknown
- 1996-11-11 CN CN96198486A patent/CN1215993A/zh active Pending
- 1996-11-11 BR BR9611626A patent/BR9611626A/pt not_active Application Discontinuation
- 1996-11-11 JP JP9519364A patent/JPH10513481A/ja active Pending
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/xx unknown
- 1996-11-11 NZ NZ322053A patent/NZ322053A/xx unknown
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/ko not_active Ceased
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/hu unknown
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/fr not_active Application Discontinuation
- 1996-11-11 SK SK630-98A patent/SK63098A3/sk unknown
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/cs unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/fr unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/fr unknown
- 1996-11-20 AR ARP960105252A patent/AR004335A1/es unknown
- 1996-11-20 YU YU62096A patent/YU62096A/sh unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/xx unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/es not_active Application Discontinuation
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/hr not_active Application Discontinuation
- 1996-11-21 CO CO96061449A patent/CO4480020A1/es unknown
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
1998
- 1998-03-31 IS IS4706A patent/IS4706A/is unknown
- 1998-05-08 BG BG102438A patent/BG102438A/xx unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/es unknown
- 1998-05-20 NO NO982302A patent/NO982302L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TNSN96141A1 (fr)	2005-03-15
BG102438A (en)	1999-01-29
GB9523752D0 (en)	1996-01-24
AP9600883A0 (en)	1997-01-31
KR19990071505A (ko)	1999-09-27
AR004335A1 (es)	1998-11-04
CA2232715A1 (fr)	1997-05-29
MX9804008A (es)	1998-09-30
AU7572196A (en)	1997-06-11
HUP9903734A2 (hu)	2000-03-28
SK63098A3 (en)	1999-05-07
YU62096A (sh)	1999-03-04
BR9611626A (pt)	1999-06-01
PL326981A1 (en)	1998-11-09
MA26410A1 (fr)	2004-12-20
PE22898A1 (es)	1998-05-07
NZ322053A (en)	1999-11-29
AP718A (en)	1999-01-06
CO4480020A1 (es)	1997-07-09
OA10687A (en)	2002-11-27
EP0862437A1 (fr)	1998-09-09
NO982302L (no)	1998-07-17
NO982302D0 (no)	1998-05-20
WO1997018814A1 (fr)	1997-05-29
IS4706A (is)	1998-03-31
JPH10513481A (ja)	1998-12-22
TR199800902T2 (xx)	1998-09-21
AU709560B2 (en)	1999-09-02
HUP9903734A3 (en)	2000-04-28
CN1215993A (zh)	1999-05-05
HRP960554A2 (en)	1998-02-28
CZ155498A3 (cs)	1999-03-17

Publication	Publication Date	Title
ZA967745B (en)	1998-03-13	Pharmaceutical formulations.
ZA969722B (en)	1998-05-20	Pharmaceutical formulations.
ZA967034B (en)	1997-02-20	Pharmaceutical compositions.
ZA965190B (en)	1997-12-19	Pharmaceutical composition.
ZA962338B (en)	1997-09-22	Oral 2-methyl-thieno-benzodiazepine formulation.
CY2359B1 (en)	2004-06-04	Pharmaceutical formulation.
AP9500733A0 (en)	1995-04-30	Pharmaceutical formulations
HU9603495D0 (en)	1997-02-28	1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, as pharmaceutical agents
GB9519363D0 (en)	1995-11-22	Pharmaceutical formulation
ZA969176B (en)	1998-04-30	Stable freeze-dried pharmaceutical formulation.
ZA951781B (en)	1995-09-05	Pharmaceutical formulations
ZA968081B (en)	1998-03-26	Pharmaceutical composition.
GB9523566D0 (en)	1996-01-17	Pharmaceutical formulation
ZA9610589B (en)	1998-01-16	Pharmaceutical compounds.
ZA96392B (en)	1996-08-29	Pharmaceutical formulations
GB9413542D0 (en)	1994-08-24	Pharmaceutical formulations
GB9500978D0 (en)	1995-03-08	Pharmaceutical formulations
ZA957349B (en)	1997-03-03	Pharmaceutical formulations.
ZA972387B (en)	1997-12-10	Pharmaceutical formulations.
GB9516584D0 (en)	1995-10-11	Pharmaceutical formulations
GB9508989D0 (en)	1995-06-21	Pharmaceutical formulations
GB9503752D0 (en)	1995-04-12	Pharmaceutical formulations
ZA968757B (en)	1998-04-17	Novel formulations.
ZA9710675B (en)	1998-05-28	Pharmaceutical formulation.
ZA976795B (en)	1998-03-20	Pharmaceutical formulation.